Chimerix GAAP EPS of -$0.25 beats by $0.01, revenue of $0.06M misses by $0.25M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Performance: Chimerix reported a Q4 GAAP EPS of -$0.25, slightly beating expectations, while revenue increased to $57K but fell short of estimates by $0.25M. The company has a strong balance sheet with $140.1 million in capital and no debt.
Market Developments: Chimerix is gaining attention due to an FDA priority review for its brain tumor drug, which could position it as a potential leader in treating recurrent high-grade glioma patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
